Toripalimab-tpzi (Loqtorzi)
Dilution requiredFull monograph review pending
U.S. label preparation
Loqtorzi · Dilution required
- Preparation
- Add the required volume to a 100 or 250 mL bag of 0.9% sodium chloride. Target 1-3 mg/mL.
- Administration and handling
- Use the labeled 0.2- or 0.22-micron in-line filter and follow the infusion schedule.
Product and source details
Coherus Oncology, Inc. · BLA761240
Product NDC: 70114-340
SPL effective 2026-07-23 | SPL version 9. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.